ReviewCancers2019
Developing Picornaviruses for Cancer Therapy.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Humanized Murine Glioblastoma Models for Evaluation of Coxsackievirus Oncolytic Therapy.Cancers · 2026Article
- Comparative analyses for plant virus-based cancer immunotherapy drug development.Cell biomaterials · 2025Article
- Polycytidine tract deletion from microRNA-detargeted oncolytic Mengovirus optimizes the therapeutic index in a murine multiple myeloma model.Molecular therapy oncolytics · 2023Article
- A physiologically based pharmacokinetic model for V937 oncolytic virus in mice.Frontiers in pharmacology · 2023Article
- High-resolution structural analysis of enterovirus-reactive polyclonal antibodies in complex with whole virions.PNAS nexus · 2022Article
- Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer.Nature communications · 2022Article
- Reverse-Phase Ultra-Performance Chromatography Method for Oncolytic Coxsackievirus Viral Protein Separation and Empty to Full Capsid Quantification.Human gene therapy · 2022Article
- Viruses as tools in gene therapy, vaccine development, and cancer treatment.Archives of virology · 2022Review
- SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus.Molecular therapy oncolytics · 2022Article
- Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?Molecular therapy oncolytics · 2022Review
- Cytolytic Properties and Genome Analysis of RigvirViruses · 2022Article
- Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.Frontiers in immunology · 2022Review
- MicroRNA-detargeting proves more effective thanMolecular therapy oncolytics · 2021Article
- The long-lasting enigma of polycytidine (polyC) tract.PLoS pathogens · 2021Review
- Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.Journal of hematology & oncology · 2021Review
- Virome assembly and annotation in brain tissue based on next-generation sequencing.Cancer medicine · 2020Article
- Article
- Review
- Efficacy and Safety of Oncolytic Viruses in Randomized Controlled Trials: A Systematic Review and Meta-Analysis.Cancers · 2020Review
- Correction: McCarthy, C.; et alCancers · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic viruses (OVs) form a group of novel anticancer therapeutic agents which selectively infect and lyse cancer cells. Members of several viral families, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.